eligibility_summary
Adults (≥18) with classic follicular lymphoma (WHO 2022), ECOG 0–2, no prior systemic therapy, need systemic treatment (≥1 GELF), FDG-avid measurable disease, Phase III: stage II–IV, FLIPI 2–5, adequate organ function. Exclude: grade 3B/FL large B-cell or suspected transformation, contraindication to BR/RCVP/R-CHOP, CNS lymphoma, >5000 circulating lymphoma cells, active/uncontrolled infection requiring systemic therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study: Phase III in untreated follicular lymphoma. Interventions and mechanisms: - AZD0486: fully human bispecific monoclonal antibody (IgG4). Specific targets not stated in record, intended to engage immune effectors to kill malignant B cells. - Rituximab: chimeric anti-CD20 IgG1 monoclonal antibody, depletes CD20+ B cells via ADCC, CDC, and apoptosis. Comparator regimens: - R-CHOP: rituximab + cyclophosphamide (alkylating DNA crosslinker), doxorubicin (anthracycline, topoisomerase II inhibitor/ROS), vincristine (microtubule inhibitor), prednisone (corticosteroid). - R-CVP: R-CHOP without doxorubicin. - BR: bendamustine (alkylating agent) + rituximab. Cells/pathways targeted: CD20+ follicular B cells, immune effector pathways (FcγR-mediated ADCC, complement/CDC, T/NK-mediated cytotoxicity), DNA damage/repair pathways (alkylators), topoisomerase II, microtubules, and glucocorticoid receptor signaling.